InVivo Therapeutics Holdings Corp.
One Kendall Square, Suite B14402
Cambridge, MA 02139
November 17, 2022
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|Re:||InVivo Therapeutics Holdings Corp.|
|Registration Statement on Form S-1|
|File No. 333-268256|
|Request for Acceleration|
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, InVivo Therapeutics Holdings Corp. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-268256), so that it may become effective at 4:00 p.m. on November 21, 2022, or as soon thereafter as practicable.
[Remainder of Page Intentionally Left Blank]
|Very truly yours,|
|INVIVO THERAPEUTICS HOLDINGS CORP.|
|By:||/s/ Richard Toselli|
|Name: Richard Toselli|
|Title: President and Chief Executive Officer|
Signature Page to Acceleration Request